Want to stay in touch with the latest updates from Pharmaceutical Business review? That's easy! Just subscribe clicking the Follow button below, choose topics or keywords for filtering if you want to, and we send the news to your inbox, to your phone via push notifications or we put them on your personal page here on follow.it.
Reading your RSS feed has never been easier!
Website title: Pharmaceutical Business review
Is this your feed? Claim it!
The combination is intended for patients who have previously received at least one line of therapy that included both a proteasome inhibitor and an immunomodulatory agent.
Zenbexus is said to be the first cereblon E3 ligase modulator (CELMoD) therapy approved by the FDA for MM treatment. Continued approval for this indication may depend on confirmation of clinical bene...
The collaboration aims to develop new quantum algorithms that could accelerate the design of next-generation photosensitisers for photodynamic therapy, a non-invasive treatment approach targeting tumour cells.
The project combines Xanadu’s algorithms team and the University of Alberta chemistry professor Alex Brown.
They will work jointly to create a quantum com...
The decision marks the third NMPA-approved indication for an ivonescimab-containing regimen in the country since the molecule first received authorisation in May 2024.
Ivonescimab is described as an investigational bispecific antibody. The latest marketing authorisation is based on data from the HARMONi-6 multi-centre Phase III study that was conducted in China.
The proceeds will also be used to fund Remepy’s lead product Hybridopa’s global Phase III clinical trial targeting Parkinson’s disease (PD). It is set to commence in the fourth quarter of 2026.
The latest funding brings the total capital raised by the company to $62m.
The Series A round was led by OG Venture Partners and M Ventures, Merck KGaA, Darmstadt, German...
The arrangement enables Sentynl to acquire exclusive US commercial rights to alvelestat upon exercise of the option while Mereo BioPharma will retain commercial rights outside the US.
Under the deal, Mereo BioPharma will receive a non-refundable option fee from Sentynl.
If Sentynl exercises the option, Mereo BioPharma will be eligible for $40m in upfront and res...